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After having analyzed the ‘‘dark sides’’
of CD95 in brain and in glioblastoma
(Kleber et al., 2008; Martin-Villalba et al.,
1999), the group of Ana Martin-Villalba
has now provided evidence that CD95 is
not just a killer but can also be beneficial
for brain repair (Corsini et al., 2009; Zuliani
et al., 2006). Thus, targeting CD95-medi-
ated neurogenesis could potentially be
a useful strategy for the treatment of
a wide range of neurological diseases.
However, the three-faceted role of CD95
in the brain also makes this receptor a
dangerous therapeutic target. Taken
together, the recent body of work on the
complex role of CD95 in the brain
suggests that, the intracellular regulatory
network of CD95 may be instrumental in
regulating whether CD95 will act to stimu-
late proapoptotic, proneurogenic, or even
protumorigenic signaling pathways. Addi-
tional work to further elucidate the regula-
tory network of CD95 will thus be needed
to identify specific targets downstream of
CD95 that will serve to direct the CD95
inducing signal specifically along neurore-
generative pathways while bypassing
apoptosis.
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In a recent report in Nature, Cordes et al. (2009) demonstrate that miR-143 and miR-145 modulate
smooth muscle cell (SMC) plasticity in part by regulating key transcription factors involved in SMC fate
determination.Recent studies have established micro-
RNAs (miRNAs) as a class of critical medi-
ators involved in the regulation of cell
proliferation and differentiation in cardiac
(van Rooij et al., 2007; Zhao et al., 2007),
skeletal (Chen et al., 2006), and smooth
(Cheng et al., 2009) muscles. In addition,
miRNAs have also been demonstrated to
play a role in the maintenance of embry-
onic stem cell (ESC) pluripotency (Xu et al.,
2009). Cordes et al. (2009) now link the
function of miRNAs to smooth muscle cell
(SMC) fate determination and plasticity
by showing that miR-143 and miR-145
regulate the proliferation and differentia-
tion of vascular SMCs.
During the early embryonic stages of
vasculogenesis, SMCs and their progeni-130 Cell Stem Cell 5, August 7, 2009 ª2009 Etors are highly proliferative and migratory.
However, in adult blood vessels, SMCs
become quiescent and express a reper-
toire of contractile, calcium regulatory,
and signal transduction proteins neces-
sary for the contractile function of fully
differentiated SMCs (Owens et al., 2004).
Further, SMCs, unlike cardiac and skel-
etal myocytes, are not terminally differen-
tiated and are capable of regaining their
highly proliferative and migratory charac-
teristics under certain conditions such as
vascular injury. Expression of nearly all
SMC marker genes is known to be
dependent upon one or more serum
response elements (SRE, CC(AT)6GG
or CArG boxes) in their promoters/
enhancers. Serum response factor (SRF)lsevier Inc.is known to regulate growth response
genes as well as muscle-specific genes
through its interaction with the muscle
cell-enriched SRF cofactor myocardin
(Wang et al., 2001). Further, it is well
documented that SRF cofactors, many
of which are antagonistic in action, are
mechanistically involved in regulating
phenotypic switching of SMCs between
proliferation and differentiation, thus
providing a molecular explanation of cell
fate maintenance and change at the tran-
scriptional level (Owens et al., 2004;
Wang et al., 2004). However, the func-
tional significance of miRNAs during
SMC differentiation remains uncertain. In
particular, whether a specific miRNA is
both necessary and sufficient to induce
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SMCs in vitro and in vivo remains to be
determined.
The Srivastava lab previously reported
that miR-143 expression is dramatically
increased when ESCs were induced to
differentiate into cardiomyocytes (Ivey
et al., 2008). In their most recent report,
Cordes et al. (2009) convincingly demon-
strate that miR-143 and miR-145, which
are clustered together and initially tran-
scribed as a single transcript, are highly
expressed in the developing heart and in
vascular SMCs. The cardiac and smooth
muscle expression pattern of miR-143/
145 parallels that of myocardin, which
(not surprisingly) was found to be SRF/
myocardin dependent. After the initial
analysis of miR-143 and miR-145 expres-
sion during development, Cordes et al.
(2009) examined miR-143 and miR-145
expression as a function of phenotypic
switching in a carotid artery ligation model.
In agreement with a prior study (Cheng
et al., 2009), the authors demonstrate
a reduction in miR-143/145 expression in
the neointimal lesion after vascular injury.
In support, Cordes et al. (2009) showed
that lentiviral delivery of miR-145 in postin-
jured carotid arteries induced the expres-
sion of some, but not all, SMC marker
genes. This observation is consistent with
the view that miR-145 inhibits ESC self-
renewal and proliferation while it concur-
rently promotes cellular differentiation (Xu
et al., 2009), suggesting that miR-143/145
negatively regulate cell proliferation in this
setting.
Gain-of-function and loss-of-function
approaches were applied to fibroblasts
and multipotent neural crest stem cells
in vitro to demonstrate that miR-145 was
both sufficient and necessary for SMC
differentiation. One of the most striking
observations revealed by Cordes et al.
(2009) was thatmiR-145 actually enhanced
myocardin-mediated SM gene expression
and SMC conversion. This finding is in
contrast to the generally accepted view
that miRNAs degrade mRNA targets and/
or repress protein translation. Searching
for the molecular mechanism, the authors
found that miR-145 increased, rather than
decreased, luciferase activity in the pres-
ence of the Myocd 30UTR. Additionally,
miR-143 and miR-145 were found to inhibit
luciferase activity in the presence of either
the Elk1 or Klf4 30UTR. Together, these
results suggest that miR-143/145 posi-tively induces the differentiation of quies-
cent SMCs by simultaneously repressing
Elk-1 and Klf4 expression while inducing
the expressionof myocardin.Complicating
these results is the observation that the
Myocd 30UTR mediated a repression in
luciferase activity in Cos cells but not in
293T cells. Although the underlying mech-
anism remains unclear, it will be interesting
to test whether a similar repression exists
in 10T1/2 fibroblasts, in which miR-145
was not able to induce smooth muscle
differentiation, and in neural crest stem
cells, in which miR-145 potently induced
smooth muscle differentiation. Whether
the activation of myocardin by miR-145 is
constitutively or contextually dependent
upon the Myocd 30UTR is an important
question that warrants further investiga-
tion. Furthermore, elucidation of the mech-
anism whereby miR-145 activates myocar-
din may be of great clinical significance,
given the ability of ectopic miR-145 to
inhibit neointimal formation in balloon-
injured carotid arteries (Cheng et al., 2009).
Though multiple miRNAs can target a
single mRNA for translational repression
and/or degradation, a single miRNA can
induce translational repression and/or
degradation of multiple mRNAs. Intrigu-
ingly, the data presented by Cordes et al.
(2009) would suggest rather that miR-143/
145 both initiates and maintains the
smooth muscle differentiation program
through enhancement of myocardin
expression and activity. The authors
suggest that miR-145 promotes SMC
differentiation ‘‘in part by increasing My-
ocd [myocardin] protein and functioning
in a feed-forward reinforcement of its
own expression by the SRF-Myocd [myo-
cardin] complex’’ whereas miR-143
represses Elk-1 and Klf4, SRF cofactors
that inhibit smooth muscle differentiation.
Interestingly, miR-145 expression is also
under the control of Oct4, in that highly
expressed Oct4 inhibits miR-145 tran-
scription in pluripotent ESCs (Xu et al.,
2009). Upon ESC differentiation, Oct4
and other pluripotent transcription factors
are downregulated, leading to the
expression of miR-145. miR-145, in turn,
suppresses pluripotency and promotes
cellular differentiation, in part, by repres-
sing the level of Oct4, Sox2, and Klf4.
Thus, we have learned that miRNAs and
their transcriptional regulators can modu-
late each other’s expression and hence
transcriptional activity, in a positive feed-Cell Stem Ceback, feed-forward, or double-negative
feedback mechanism. It is therefore
speculated that we will see similar
miRNA-dependent mechanisms in vari-
ous biological systems that maintain
precise cellular homeostasis during
development, cell proliferation, differenti-
ation, and apoptosis.
Although the study by Cordes et al.
(2009) revealed some very interesting
functions of miRNAs in SMCs, with the
implication of potential miRNA-based
cardiovascular and cancer therapeutics,
one should keep in mind that many of
the conclusions were based upon in vitro
experimental systems or overexpression
approaches. For example, if miR-145 is
required for myocardin activity during
smooth muscle differentiation in vitro,
one would expect that miR-145 knockout
mice will phenocopy myocardin knockout
mice, as predicted by the model of
Cordes et al. (2009). Similarly, one would
also predict that miR-143/145 null animals
would exhibit defects in ESC self-renewal,
proliferation, and cell fate commitment,
given the vital role of those miRNAs
reported by Cordes et al. (2009) and
Xu et al. (2009). The in vivo biological
role of miR-143/145, though uncertain,
may prove to be a pivotal regulatory factor
in ESC self renewal, cell fate commitment,
and maintenance of the quiescent
SMC phenotype. Determination of the
upstream regulatory signals (normal or
pathological) that modulate both the
magnitude and temporal control of miR-
143/145 expression will greatly enhance
our understanding of the SMC differentia-
tion program.
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In a recent Nature publication, Lepp
lable gene deletion approaches to s
for Pax gene expression.
The demands on tissue-specific stem
cells undergo dramatic modifications as
the functional requirements of the tissue
they serve change throughout develop-
ment, growth, and adult life. Skeletal
muscle stem cells or satellite cells are
quiescent cells located between the
muscle fiber sarcolemma and the basal
lamina surrounding the fiber. This popula-
tion is responsible for replenishing the
stem cell pool and providing a source of
differentiated progeny for myofiber repair
after injury (Charge and Rudnicki, 2004).
The ability of these cells to provide a
continual source of differentiated progeny
during multiple rounds of damage and
repair indicates that at least a subpopula-
tion of satellite cells possess stem cell
properties. In neonatal muscle, satellite
cells are primarily proliferating and provide
a critical source of differentiated nuclei for
myofiber growth (Schultz, 1996). Whether
there are different molecular mechanisms
that govern stem cell function at distinct
stages throughout life has remained
elusive. Now, Lepper et al. (2009) have
made significant progress in answering
this question by directly demonstrating
that the genetic requirement for Pax7 is
altered in satellite cells during the transi-
tion from development to adulthood.
Pax7 was defined as a specific marker
of satellite cells and their precursors
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er et al. (2009) use cell-specific linea
tudy muscle stem cell function and r
present in adult and embryonic skeletal
muscle, respectively (Relaix et al., 2005;
Seale et al., 2000). The first appearance
of Pax7-expressing cells that reside
beneath the basal lamina, and that there-
fore fulfill the definition of a satellite cell,
occurs at approximately E16.5 in the
mouse embryo (Kassar-Duchossoy et al.,
2005). Experiments in Pax7-deficient
mice have previously shown that forma-
tion of the satellite cell pool in the embryo
appears to be Pax7 independent, whereas
the specification of the adult satellite cell
pool appears Pax7 dependent (Seale
et al., 2000; Relaix et al., 2005; Oustanina
et al., 2004). The severe postnatal pheno-
type has thus far prevented analysis of
the specific function of Pax7 in adult
satellite cells.
Lepper and colleagues have bypassed
this previous limitation by using temporally
inducible Cre/lox technology to dissect
the role of Pax7 in satellite cells in post-
natal and adult regenerating muscle.
Their findings provide unanticipated
insight into the molecular regulation of
the Pax7+ satellite cell pool as it transitions
from a ‘‘neonatal’’ into an ‘‘adult’’ stage.
The authors demonstrate that in re-
sponse to injury, the complement of
Pax7-expressing satellite cells present in
neonatal muscle exhibit a requirement
for Pax7 that is subsequently lost in the
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eveal age-dependent requirements
Pax7-derived satellite cells of adult
muscle.
Transplantation assays have demon-
strated that subpopulations of adult satel-
lite cells have stem cell potential (Collins
et al., 2005). The utilization of genetic
lineage markers to trace the endogenous
muscle stem cell pool (Lepper et al.,
2009) provides an alternative method to
transplantation assays whereby the full
endogenous pool of stem cells can partic-
ipate in the regeneration response and
may reflect a more physiologically rele-
vant stem cell capability within the native
environment. Lepper and colleagues
genetically label Pax7-expressing cells
and can trace the Pax7 cells and their
progeny over time. The authors found
that adult Pax7-derived cells proliferate
in response to injury and contribute to
both muscle fiber repair and the renewing
satellite cell pool in their endogenous
environment. During a second round of
injuries, a subpopulation of satellite cells
with a Pax7 origin again contribute to
myofiber repair, demonstrating the
self-renewing capacity of this fraction
under conditions of muscle damage and
repair.
Lepper and colleagues also disrupted
Pax7 function in Pax7-derived cells in
postnatal and adult mice. Analysis of
subsequent injury-induced regeneration
